ArticleFrontiers in pharmacology2019
Prospects for the Use of New Technologies to Combat Multidrug-Resistant Bacteria.
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 96 citations in OpenAlex.
- Developing new technologies to protect ecosystems: Planning with adaptive management.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Unveiling the Antibacterial Efficacy and Mechanistic Insights of MnOInternational journal of molecular sciences · 2025Article
- Developing a Versatile Arsenal: Novel Antimicrobials as Offensive Tools Against Pathogenic Bacteria.Microorganisms · 2025Review
- Advances in nanomaterial-mediated CRISPR/Cas delivery: from lipid nanoparticles to vesicle-derived systems.Frontiers in bioengineering and biotechnology · 2025Review
- Improving Activity of New Arylurea Agents against Multidrug-Resistant and Biofilm-ProducingACS medicinal chemistry letters · 2024Article
- Potential of an Isolated Bacteriophage to InactivateAntibiotics (Basel, Switzerland) · 2024Article
- Liposome-Based Antibacterial Delivery: An Emergent Approach to Combat Bacterial Infections.ACS omega · 2023Review
- A comprehensive review on potential applications of metallic nanoparticles as antifungal therapies to combat human fungal diseases.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Review
- Newly Isolated Virulent Salmophages for Biocontrol of Multidrug-ResistantInternational journal of molecular sciences · 2023Article
- Article
- The role of efflux pumps ın antıbıotıc resıstance of gram negatıve rods.Archives of microbiology · 2023Review
- Analysis of Capped Silver Nanoparticles Combined with Imipenem against Different Susceptibility Profiles ofAntibiotics (Basel, Switzerland) · 2023Article
- Phage engineering and phage-assisted CRISPR-Cas delivery to combat multidrug-resistant pathogens.Bioengineering & translational medicine · 2023Review
- Current Promising Strategies against Antibiotic-Resistant Bacterial Infections.Antibiotics (Basel, Switzerland) · 2022Review
- Nanomaterials for Delivering Antibiotics in the Therapy of Pneumonia.International journal of molecular sciences · 2022Review
- Mutagenesis and Resistance Development of Bacteria Challenged by Silver Nanoparticles.Antimicrobial agents and chemotherapy · 2022Article
- Isolation and Molecular Characterization of a Novel Lytic Bacteriophage That Inactivates MDRPharmaceutics · 2022Article
- Effect of Biosynthesized Silver Nanoparticles on Bacterial Biofilm Changes inNanomaterials (Basel, Switzerland) · 2022Article
- Recent Advances in Antimicrobial Nano-Drug Delivery Systems.Nanomaterials (Basel, Switzerland) · 2022Review
- Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics.Antibiotics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing use of antibiotics is being driven by factors such as the aging of the population, increased occurrence of infections, and greater prevalence of chronic diseases that require antimicrobial treatment. The excessive and unnecessary use of antibiotics in humans has led to the emergence of bacteria resistant to the antibiotics currently available, as well as to the selective development of other microorganisms, hence contributing to the widespread dissemination of resistance genes at the environmental level. Due to this, attempts are being made to develop new techniques to combat resistant bacteria, among them the use of strictly lytic bacteriophage particles, CRISPR-Cas, and nanotechnology. The use of these technologies, alone or in combination, is promising for solving a problem that humanity faces today and that could lead to human extinction: the domination of pathogenic bacteria resistant to artificial drugs. This prospective paper discusses the potential of bacteriophage particles, CRISPR-Cas, and nanotechnology for use in combating human (bacterial) infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.